We would love to hear your thoughts about our site and services, please take our survey here.
May? But I need this to pay off Monday.
It is a good question - big pharma rushed out their therapies with less data and landed nice contracts with governments. To be honest, I wish SNG mgt would have partnered with big pharma…this would have been rolled out sooner.
Hahaha Mr daf, thank you for the light hearted satire of some members’ attempts to divine meaning from a blink or intonation. It’s all in good fun while we watch the clock tick by.
Nice. Thank you.
Deployed by Bill Gates no less! Lol
I would suggest factoring in the source and conflict of interest of the researchers
Oakleaf, you may be the proverbial crazy old geezer sitting in the corner of the pub screaming at strangers but you may be right on this occasion.
Junior trader getting nervous ?
Anyone have 495€ on them?
Low efficacy, questionable trial and mutagenic
How does one distinguish between a deramper from an honest investor who merely wants to play devils advocate to stress test his or her bull thesis? How does one distinguish a pump and dump artist from an honest investor?
Instead or dwelling on a witch hunt, why not be a sponge of all information and decide for oneself or through open discussion?
As for GameStop, that is way overvalued and different dynamics than SNG, which has a legitimate bull case, ie it was a short squeeze.
I believe it is because clinical stage biotech and tech are both considered “risk on” trades.
City, credibility is one thing that when lost is very difficult to reclaim.
Wall Street Bets and meme stocks is a US phenomenon. SYGGF (SNG’s ticker in the US) trades OTC with little liquidity. This isn’t their typical play.
Given what is happening in the equity markets globally, SNG is a sea of calm.
Thanks city.
Very skeptical about the rumors of the new buyer being Maverick. It just isn't their modus operandi. It would be wonderful though, as they have a reputation for seeing quality in mgt and value in certain businesses.
https://www.mckinsey.com/business-functions/strategy-and-corporate-finance/our-insights/inside-a-hedge-fund-an-interview-with-the-managing-partner-of-maverick-capital
No forecast on either commercial venture + no comment on cash burn + unjustifiable market cap during a "risk off" period in the market.
Hi Nick, there are 3 things the management should be communicating to investors:
1. update on SkinBiotix - this has progressed enough for one to expect some forecast on revenue
2. update on AxisBiotix-Ps - At the minimum, I would expect commentary on "clicks" to the adverts
3. cash burn - I would expect some comment on any increase spend directed to their investigation on acne or other ailments. With £4.6m, and cash burn of approx £1.5m pa, that does not leave much time before another dilution event.
Flipping through the RNS, it lacks anything concrete, i.e. figures - not a single mention from mgt of either anticipated revenue or their approach to expense mgt. This vagueness is not enough to support the £85m market cap seen a few days ago and the price is collapsing accordingly.
For an additional tenner, Elrico will give you access to his podcast of Enron's CEO telling him that his company is amazing.